Stock Alert: Immuron Jumps 51% On Research Deal With Australia's CSIRO

(RTTNews) - Shares of Australian biopharma company Immuron Ltd. (IMRN) are gaining more than 51 percent or $4.00 in Friday's morning trade at $11.75.

Friday, Immuron said it has executed a research agreement with Australia's national science agency, CSIRO, to produce a new oral therapeutic against Campylobacter and Entero-Toxigenic Escherichia coli or ETEC for clinical evaluation by the US Department of Defense. Under the terms of the deal, CSIRO has been engaged to produce a hyper-immune bovine colostrum product using vaccines developed by the Naval Medical Research Center or NMRC. The stock has traded in a range of $1.55 to $28.99 in the past 52 weeks.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Latest Markets Videos


Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

Learn More